Skip to Content
Merck
  • Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF.

Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF.

Autophagy (2014-12-17)
Monique Bernard, Mélanie Dieudé, Bing Yang, Katia Hamelin, Katy Underwood, Marie-Josée Hébert
ABSTRACT

Recent evidence suggests that autophagy may favor fibrosis through enhanced differentiation of fibroblasts in myofibroblasts. Here, we sought to characterize the mediators and signaling pathways implicated in autophagy-induced myofibroblast differentiation. Fibroblasts, serum starved for up to 4 d, showed increased LC3-II/-I ratios and decreased SQSTM1/p62 levels. Autophagy was associated with acquisition of markers of myofibroblast differentiation including increased protein levels of ACTA2/αSMA (actin, α 2, smooth muscle, aorta), enhanced gene and protein levels of COL1A1 (collagen, type I, α 1) and COL3A1, and the formation of stress fibers. Inhibiting autophagy with 3 different class I phosphoinositide 3-kinase and class III phosphatidylinositol 3-kinase (PtdIns3K) inhibitors or through ATG7 silencing prevented myofibroblast differentiation. Autophagic fibroblasts showed increased expression and secretion of CTGF (connective tissue growth factor), and CTGF silencing prevented myofibroblast differentiation. Phosphorylation of the MTORC1 target RPS6KB1/p70S6K kinase was abolished in starved fibroblasts. Phosphorylation of AKT at Ser473, a MTORC2 target, was reduced after initiation of starvation but was followed by spontaneous rephosphorylation after 2 d of starvation, suggesting the reactivation of MTORC2 with sustained autophagy. Inhibiting MTORC2 activation with long-term exposure to rapamycin or by silencing RICTOR, a central component of the MTORC2 complex abolished AKT rephosphorylation. Both RICTOR silencing and rapamycin treatment prevented CTGF and ACTA2 upregulation, demonstrating the central role of MTORC2 activation in CTGF induction and myofibroblast differentiation. Finally, inhibition of autophagy with PtdIns3K inhibitors or ATG7 silencing blocked AKT rephosphorylation. Collectively, these results identify autophagy as a novel activator of MTORC2 signaling leading to CTGF induction and myofibroblast differentiation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Wortmannin, Ready Made Solution, from Penicillium funiculosum, ≥95% (HPLC)
Sigma-Aldrich
Rapamycin, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
3-Methyladenine, autophagy inhibitor
Sigma-Aldrich
LY 294002, LY294002, CAS 154447-36-6, is a cell-permeable, potent, reversible, and specific inhibitor of PI 3-kinase ((IC50 = 1.4 µM). Acts on the ATP-binding site.
Sigma-Aldrich
Autophagy Inhibitor, 3-MA, Autophagy Inhibitor, 3-MA, CAS 5142-23-4, is a cell-permeable autophagic sequestration blocker. Acts as an inhibitor of III PI3-Kinase.
Supelco
Rapamycin, VETRANAL®, analytical standard
Sigma-Aldrich
Donkey serum
Sigma-Aldrich
Monoclonal Anti-Actin, α-Smooth Muscle, clone 1A4, ascites fluid
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Bafilomycin A1 from Streptomyces griseus, ≥90% (HPLC)
Sigma-Aldrich
Rapamycin from Streptomyces hygroscopicus, ≥95% (HPLC), powder
Sigma-Aldrich
Anti-α-Tubulin Mouse mAb (DM1A), liquid, clone DM1A, Calbiochem®
Sigma-Aldrich
Anti-Smad2/3 Antibody, Upstate®, from rabbit